The potential role of interleukins and interferons in ovarian cancer

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2023-11, Vol.171, p.156379-156379, Article 156379
• Main Authors: Huldani, Huldani, Abdul-Jabbar Ali, Sana, Al-dolaimy, F., Hjazi, Ahmed, Denis Andreevich, Nikolenko, Oudaha, Khulood H., Almulla, Abbas F., Alsaalamy, Ali, Kareem Oudah, Shamam, Mustafa, Yasser Fakri
• Format: Article
• Language: English
• Subjects: Cancer therapy; Cytokines; Interferon; Interleukin; Ovarian carcinoma
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2023.156379

•ILs play crucial function in ovarian cancer.•IFNs role in prevention or development of ovarian cancer.•ILs and IFNs can be applied in ovarian cancer therapy. Ovarian cancer poses significant challenges and remains a highly lethal disease with limited treatment options. In the context of ovarian cancer, interleukins (ILs) and interferons (IFNs), important cytokines that play crucial roles in regulating the immune system, have emerged as significant factors influencing its development. This article provides a comprehensive review of the involvement of various ILs, including those from the IL-1 family, IL-2 family, IL-6 family, IL-8 family, IL-10 family, and IL-17 family, in ovarian cancer. The focus is on their impact on tumor growth, metastasis, and their role in evading immune responses within the tumor microenvironment. Additionally, the article conducts an in-depth examination of the oncogenic or antitumor roles of each IL in the context of ovarian cancer pathogenesis and progression. Besides, we elucidated the enhancements in the treatment of ovarian cancer through the utilization of type-I IFN and type-II IFN. Recent research has shed light on the intricate mechanisms through which specific ILs and IFNs contribute to the advancement of the disease. By incorporating recent findings, this review also seeks to inspire further investigations into unexplored mechanisms, fostering ongoing research to develop more effective therapeutic strategies for ovarian cancer. Moreover, through an in-depth analysis of IL- and IFN-associated clinical trials, we have highlighted their promising potential of in the treatment of ovarian cancer. These clinical trials serve to reinforce the significant outlook for utilizing ILs and IFNs as therapeutic agents in combating this disease.